MB-106,Cyclophosphamide
fortress biotech,mustang bio
[]
#eha2023: mb-106, a cd20-targeted, autologous car-t #celltherapy, has potential to become an outpatient treatment option for wm (a rare blood #cancer for which there are no fda-approved treatments), as well as other b-cell malignancies. $mbio 
Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.